Imugene (ASX:IMU) has announced that a bile tract cancer patient in its Phase 1 MAST trial remains a complete response, now surpassing more than two years in remission. …
Immugene says bile tract cancer patient maintains complete response in MAST study
November 5, 2024 Australian Biotech
Latest Video
New Stories
-
The Dispatched 'Week in Review' Podcast - 3 October
October 3, 2025 - - Podcast -
The challenge is for our gatekeepers. Can they see beyond the gate?
October 3, 2025 - - Latest News -
Trump administration links MFN and lower prices to faster FDA approvals
October 3, 2025 - - Latest News -
Vertex appoints Elisha Whitfield as senior country manager for Australia and New Zealand
October 2, 2025 - - Latest News -
Race Oncology uncovers novel anticancer mechanism for bisantrene
October 2, 2025 - - Australian Biotech -
Mark Butler announces boost for clinical trial reform, after years of delay
October 2, 2025 - - Latest News -
Pharmac moves to ease access to HIV medicines in New Zealand
October 2, 2025 - - Latest News